trial
as of 2026-07-01Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
NCTId NCT05182476
at a glance
Phase 2 · Terminated
Enrollment 216 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2024-06-28
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Terminated
Enrollment
216 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-12-07
Primary completion
2024-06-28
Eligibility
ALL · 18 Years · 50 Years
Interventions & indications
Drugs
Sponsors
Neurocrine BiosciencesLead Sponsor
Investigators
1
Clinical Development LeadStudy Director
Sites
49 total
Phoenix, United StatesBentonville, United StatesBryant, United StatesAnaheim, United StatesBellflower, United StatesGarden Grove, United StatesGlendale, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United StatesSan Diego, United StatesSan Rafael, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
216
Phase
PHASE2
Primary Completion Date
2024-06-28
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator